About Filana Therapeutics Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.cassavasciences.com/
Frequently Asked Questions
What is the 52-week range for FLNA?
The 52-week high is $2.2665 and the 52-week low is $0.6701.
What is the P/E ratio for FLNA?
The P/E ratio data is currently unavailable.
What is the dividend yield for FLNA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -58.78%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 76.73%.
What is the Price to Book (P/B) Ratio?
P/B ratio data is currently unavailable.
Analyst Recommendation Trends
Wall Street analyst consensus for FLNA over the last few months:
Latest FLNA News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers DataMEDS AI (NASDAQ:MEDS) stock moved upwards by 39.4% to $4.42 during Thursday's pre-market session. The company's market cap stands at $10.1 million. Stablecoin Development (AMEX:SDEV) shares moved
These stocks are moving in today's after hours session
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's after-market session. The company's market cap stands at $1.0 billion. Filana Therapeutics (NASDAQ:FLNA) shares rose
Unusual volume stocks in Wednesday's session
Volume analysis on 2026-09-23: stocks with an unusual volume in today's session.
Gapping stocks in Wednesday's session
Let's have a look at the gap up and gap down stocks in today's session.
Which stocks are experiencing notable movement on Tuesday?
Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Which stocks are most active on Tuesday?
Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Jaguar Health (NASDAQ:JAGX) shares moved upwards by 32.2% to $45.56 during Tuesday's after-market session. The company's market cap stands at $1.1 million. Bullfrog AI Hldgs (NASDAQ:BFRG) shares
What's going on in today's session
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Gapping stocks in Tuesday's session
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Jaguar Health (NASDAQ:JAGX) stock increased by 304.5% to $10.8 during Tuesday's regular session. The company's market cap stands at $1.1 million. Greenland Mines (NASDAQ:GRML) shares moved upwards by
Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward
The FDA lifted a clinical hold on Filana Therapeutics' IND application, allowing a Phase 2a trial for a TSC-related epilepsy treatment.
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027Filana has engaged a leading clinical research organization, has identified clinical trial sites, and is recruiting potential investigatorsOngoing collaboration with the TSC Alliance and the broader TSC community is intended to support patient engagement and study execution AUSTIN, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a bio
FDA Lifts Clinical Hold Form Filana Therapeutics' Investigational New Drug Application To Initiate Planned Phase 2a Trial In Participants With Tuberous Sclerosis Complex-Related Epilepsy
Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis Complex
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-30 | Barry Richard | +100,000 | $0.92 | $92,000 |
| 2026-09-29 | Barry Richard | +206,813 | $0.9 | $186,132 |